CALGB 50803: A Phase II Trial of Lenalidomide (Revlimid (TM), CC-5013) (NSC #703813, IND#70116) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
Study Status
Open to Enrollment
Study Description
Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving lenalidomide together with rituximab may kill more cancer cells.
This phase II clinical trial is studying how well giving lenalidomide and rituximab together works in treating patients with stage II, stage III, or stage IV follicular non-Hodgkin lymphoma.
Click here to visit our lymphoma blog.
Disease Status and/or Stage
Untreated Follicular Lymphoma
Sponsor
CALGB
Key Eligibility
- Follicular Non-Hodgkin Lymhoma
- No prior systemic therapy for Non-Hodgkin Lymphoma, including chemotherapy or immunotherapy
- Detailed eligibility discussed when you contact the study team
Principal Investigator
Contact
- June Greenberg, RN
- (212) 746-2651
- jdg2002@med.cornell.edu
Healthy Volunteers
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
Contact Us
For general inquiries, or if you need assistance finding a study, please contact:
Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
roh2026@med.cornell.edu
